| oxaliplatin / Generic mfg. |
| Completed | 2 | 14 | Europe | Mangafodipir, Teslascan; ACT code V08CAE05, Placebo treatment (0.9% NaCl) | Egetis Therapeutics | Chemotherapy, Colon Cancer | 04/10 | 04/10 | | |
| Completed | 2 | 33 | RoW | Belotaxel, Docetaxel, Belloxa, Oxaliplatin | Chonnam National University Hospital, Chong Kun Dang Pharmaceutical | Non-Small Cell Lung Cancer | 01/13 | 01/13 | | |
NCT01863420: The Effect of Bone Marrow-sparing Intensity-Modulated Radiotherapy to GI Cancer |
|
|
| Unknown status | 2 | 58 | RoW | Bone Marrow-sparing Intensity-Modulated Radiotherapy | Chinese Academy of Medical Sciences | Rectal Cancer, Gastric Cancer, Bone Marrow Toxicity, Adverse Effect of Radiation Therapy | 10/14 | 10/15 | | |
NCT01580410: Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix |
|
|
| Completed | 2 | 136 | US | mitomycin C, MITC, MITO, MITO-C, Mitocin-C, MTC, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, therapeutic conventional surgery, quality-of-life assessment, quality of life assessment, hyperthermic intraperitoneal chemotherapy | Wake Forest University Health Sciences, National Cancer Institute (NCI) | Carcinoma of the Appendix, Primary Peritoneal Cavity Cancer | 10/15 | 11/16 | | |
2005-005548-21: Phase I-II Study of the Combination of Bevacizumab (rhuMAb VEGF) and Erlotinib (EGFR TKI) plus Oxaliplatin and Capecitabine (XELOX) in Patients with Metastatic Colorectal Cancer: XELOX-TARAV study |
|
|
| | 2 | 80 | Europe | Concentrate for solution for infusion | CONSORZIO ONCOTECH | Patients with metastatic colorectal cancer, who have not previously received systemic treatment for metastatic disease. | | | | |
NCT02624492 / 2014-004794-16: To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL |
|
|
| Completed | 2 | 21 | Europe | BI 836826, GemOx, Rituximab | Boehringer Ingelheim | Lymphoma, Large B-Cell, Diffuse | 03/18 | 03/18 | | |
NCT01516216: Study of Vitamin D in Untreated Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 139 | US | FOLFOX + bevacizumab, 5-FU (5-fluorouracil), Leucovorin, Oxaliplatin (Eloxatin), Bevacizumab (Avastin), Vitamin D | Dana-Farber Cancer Institute | Metastatic Colorectal Cancer | 11/19 | 11/19 | | |
PAMELA70, NCT02143219: Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer |
|
|
| Completed | 2 | 72 | Europe | Oxaliplatine, Eloxatine®, Folinic acid, Irinotecan, Campto®, 5-FU, 5-fluorouracile | Institut Cancerologie de l'Ouest | Pancreatic Metastatic Cancer, Toxicity | 11/20 | 11/20 | | |
NCT06353581: Prophylactic Administration of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Receiving the Modified FOLFIRINOX |
|
|
| Active, not recruiting | 2 | 78 | RoW | Neulapeg, Control | Yonsei University | Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer | 05/24 | 05/24 | | |
ChiCTR2100051884: Efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor secondary prophylaxis in capecitabine combined with oxaliplatin (CapeOX) regimen in the treatment of colorectal cancer |
|
|
| Not yet recruiting | 2 | 20 | | The test drug PEG-rhG-CSF injection was administered 24-48 hours after the end of oxaliplatin intravenous infusion | The First Affiliated Hospital of China Medical University; The First Affiliated Hospital of China Medical University, CSPC Ouyi Pharmaceutical Co., Ltd. | Colorectal cancer | | | | |
ULTIMA, NCT04611724: A Multicenter Prospective Phase II Study of Modified FOLFIRINOX for 1st Line Treatment for Advanced Urachus Cancer |
|
|
| Recruiting | 2 | 35 | RoW | FOLFIRINOX | Asan Medical Center, Green Cross Corporation, Boryung Pharmaceutical Co., Ltd | Urachal Cancer | 12/23 | 09/24 | | |
NCT05665023: Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma |
|
|
| Recruiting | 2 | 37 | RoW | Bevacizumab + modified FOLFIRINOX | Yonsei University | Mucinous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 02/24 | 02/25 | | |
NCT03875313: Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors |
|
|
| Terminated | 1b/2 | 33 | US | CB-839, telaglenastat, Talazoparib, Talzenna | Calithera Biosciences, Inc | Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer, CRC, RCC, ccRCC | 07/20 | 07/20 | | |
| Completed | 1b/2 | 213 | Europe, US, RoW | Oleclumab, MEDI9447, Durvalumab, MEDI4736, Gemcitabine, Nab-paclitaxel, Oxaliplatin, Modified FOLFOX (oxaliplatin, folinic acid, and 5-FU), Folinic acid, 5-FU | MedImmune LLC | Carcinoma, Metastatic Pancreatic Adenocarcinoma | 07/22 | 07/22 | | |
|
2012-003678-13: Phase I-II trial of gemcitabine plus nab-paclitaxel (GemBrax) followed by FOLFIRINOX as first-line treatment of patients with metastatic pancreatic adenocarcinoma |
|
|
| Not yet recruiting | 1/2 | 118 | Europe | Powder for suspension for injection, Powder for solution for infusion, Solution for infusion, Solution for injection, ABRAXANE, GEMCITABINE, OXALIPATINE, CAMPTO, FOLINATE DE CALCIUM, FLUOROURACILE | Institut Régional de Cancerologie de Montpellier - Val d’Aurelle, Laboratory CELGENE | metastatic pancreatic adenocarcinoma, Pancreatic cancer, Diseases [C] - Cancer [C04] | | | | |
NCT01955629 / 2013-000858-22: Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient |
|
|
| Terminated | 1/2 | 4 | Europe | Aflibercept AVE0005, Zaltrap, Oxaliplatin, Eloxatin, SR96669, Capecitabine | Sanofi, Regeneron Pharmaceuticals | Colorectal Cancer Metastatic | 03/15 | 03/15 | | |
NCT00526110: Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients |
|
|
| Completed | 1/2 | 98 | US | 5-Fluorouracil, 5-FU, Adrucil, Efudex, Docetaxel, Taxotere, Oxaliplatin, Eloxatin | M.D. Anderson Cancer Center, Sanofi-Synthelabo | Gastrointestinal Diseases | 06/15 | 06/15 | | |
FABLOx, NCT02620800: Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer |
|
|
| Completed | 1/2 | 12 | US | 5FU, nab-paclitaxel, Abraxane, ABI-007, bevacizumab, Avastin, calcium leucovorin, Citrovorum Factor, Folinic Acid, oxaliplatin, Elotaxin | Celgene | Metastatic Pancreas Adenocarcinoma | 10/18 | 10/18 | | |
NCT01959139: S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer |
|
|
| Completed | 1/2 | 126 | US | PEGPH20, Pegylated Recombinant Human Hyaluronidase, Oxaliplatin, Eloxatin, NSC-266046, Leucovorin, leucovorin calcium, Irinotecan, CPT-11, NSC-616348, 5-fluorouracil, 5-FU, Adrucil, NSC-19893 | SWOG Cancer Research Network, National Cancer Institute (NCI), Halozyme Therapeutics | Metastatic Pancreatic Adenocarcinoma | 04/19 | 11/23 | | |
| Completed | 1/2 | 307 | Europe, Canada, US, RoW | Axicabtagene Ciloleucel, Yescarta®, Fludarabine, Cyclophosphamide, Levetiracetam, Tocilizumab, Dexamethasone, High-dose methylprednisolone, Bendamustine, Rituximab, Doxorubicin, Prednisone, Vincristine, Ifosfamide, Carboplatin, Etoposide, Gemcitabine, Oxaliplatin, Cisplatin, Methylprednisolone | Kite, A Gilead Company | Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL) | 07/23 | 07/23 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Active, not recruiting | 1/2 | 383 | Europe, Canada, US, RoW | Monalizumab, Durvalumab, Cetuximab, mFOLFOX6, Bevacizumab | MedImmune LLC | Advanced Solid Tumors | 10/21 | 09/24 | | |
|
|
|
|
